M
Michael J. Birrer
Researcher at University of Arkansas for Medical Sciences
Publications - 579
Citations - 64433
Michael J. Birrer is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 102, co-authored 554 publications receiving 54218 citations. Previous affiliations of Michael J. Birrer include University of Texas MD Anderson Cancer Center & University of Arkansas at Little Rock.
Papers
More filters
Journal ArticleDOI
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer
Jonathan A. Ledermann,Christian Marth,Mark S. Carey,Michael J. Birrer,David D.L. Bowtell,Stan B. Kaye,Iain A. McNeish,Amit M. Oza,Giovanni Scambia,Gordon J. S. Rustin,Frederick B. Stehman,David M. Gershenson,Gillian Thomas,Els M.J.J. Berns,Antonio Casado,Nelleke Ottevanger,Felix Hilpert,Byoung-Gie Kim,Aikou Okamoto,Monica Bacon,Henry C Kitchener,Gavin Stuart +21 more
TL;DR: The 4th Ovarian Cancer Consensus Conference as discussed by the authors discussed the need to identify prognostic and predictive biomarkers to evaluate the effectiveness of antiangiogenic drugs in ovarian cancer.
Journal ArticleDOI
Workshop on imaging science development for cancer prevention and preemption.
Gary J. Kelloff,Daniel C. Sullivan,Houston Baker,Lawrence Clarke,Robert J. Nordstrom,James L. Tatum,Gary S. Dorfman,Paula M. Jacobs,Christine D. Berg,Martin G. Pomper,Michael J. Birrer,Margaret A. Tempero,Howard R. Higley,Brenda Gumbs Petty,Caroline C. Sigman,Carlo C. Maley,Prateek Sharma,Adam Wax,Gregory G. Ginsberg,Andrew J. Dannenberg,Ernest T. Hawk,Edward M. Messing,H. Barton Grossman,Mukesh G. Harisinghani,Irving J. Bigio,Donna Griebel,Donald E. Henson,Carol J. Fabian,Katherine W. Ferrara,Sergio Fantini,Mitchell D. Schnall,Jo Anne Zujewski,Wendy Hayes,Eric A. Klein,Angelo M. DeMarzo,Iclal Ocak,Jeffrey A. Ketterling,Clare M. Tempany,Faina Shtern,Howard L. Parnes,Jorge Gomez,Sudhir Srivastava,Eva Szabo,Stephen Lam,Eric J. Seibel,Pierre P. Massion,Geoffrey McLennan,Kevin Cleary,Robert D. Suh,Randall W. Burt,Ruth M. Pfeiffer,John M. Hoffman,Hemant K. Roy,Tom D. Wang,Paul J. Limburg,Wafik S. El-Deiry,Vassiliki A. Papadimitrakopoulou,Walter N. Hittelman,Calum MacAulay,Robert W. Veltri,Diane Solomonzz,Jose Jeronimo,Rebecca Richards-Kortum,Karen A. Johnson,Jaye L. Viner,Steven P. Stratton,Milind Rajadhyaksha,Atam Dhawan +67 more
TL;DR: Chemopreventive agents with high therapeutic indices, well-monitored for efficacy and safety, are greatly needed, as is development of less invasive or minimally disruptive visualization and assessment methods to safely screen nominally healthy but at-risk patients.
Journal ArticleDOI
The origin of ovarian cancer—is it getting clearer?
TL;DR: The association of endometriosis and ovarian cancer was first reported by Sampson in 1925 and most attention has been focused on serous adenocarcinoma, the most common and lethal histologic type.
Journal ArticleDOI
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer
Andrea P. Myers,Panagiotis A. Konstantinopoulos,William T. Barry,Weixiu Luo,Russell Broaddus,Vicky Makker,Ronny Drapkin,Joyce F. Liu,Austin Doyle,Neil S. Horowitz,Funda Meric-Bernstam,Michael J. Birrer,Carol Aghajanian,Robert L. Coleman,Gordon B. Mills,Lewis C. Cantley,Ursula A. Matulonis,Shannon N. Westin +17 more
TL;DR: There is limited single agent activity of MK‐2206 in PIK3CA MT and Pik3CA WT endometrial cancer populations and activity was detected in patients with serous histology and due to their poor outcomes warrants further study (NCT01307631).
Journal ArticleDOI
Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues.
Svitlana Tyekucheva,Neil E. Martin,Edward C. Stack,Edward C. Stack,Wei Wei,Vinod Vathipadiekal,Levi Waldron,Michelangelo Fiorentino,Rosina T. Lis,Rosina T. Lis,Meir J. Stampfer,Meir J. Stampfer,Massimo Loda,Giovanni Parmigiani,Lorelei A. Mucci,Lorelei A. Mucci,Michael J. Birrer +16 more
TL;DR: This study supports the feasibility of gene expression profiling and large-scale signature validation on archival prostate and ovarian tumor specimens using commercial platforms, which have the potential to aid precision medicine with biomarker discovery and validation.